|
Sign In to gain access to subscriptions and/or personal tools.
|
Primary and secondary pulmonary hypertension in systemic lupus erythematosus
T Ling-Te Pan
The Department of Rheumatology and Immunology, Tan Tock Seng Hospital, Singapore
J Thumboo
Department of Rheumatology and Immunology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore Tel: (+ 65) 357 7822; Fax: (+ 65) 357 7837 Julian_Thumboo{at}notes.ttsh.gov.sg
M-L Boey
The Department of Rheumatology and Immunology, Tan Tock Seng Hospital, Singapore
Objectives: To describe the aetiology and clinical profile of primary and secondary pulmonary hypertension (PHT) in SLE patients.
Methods: A retrospective study of SLE patients with PHT identified from a cohort of 786 SLE patients seen at Tan Tock Seng Hospital, Singapore.
Results: 22 patients had primary and 24 patients had secondary PHT, with similar clinical features at presentation and a similar degree of pulmonary pressure elevation. Secondary PHT was due to valvular heart disease (50%), pulmonary embolism (13%), interstitial lung disease (8%) or a combination of these factors (29%). Primary PHT tended to present after a shorter duration of lupus than secondary PHT (8.8 vs 43.2 months, P = 0.118). At presentation, Raynaud's phenomenon was present in 34.8% of subjects with primary or secondary PHT. Among those with secondary PHT, the presence of Raynaud's phenomenon was associated with a trend towards higher pulmonary artery systolic pressures (51.0 vs 40.5 mmHg, P = 0.101). 17% of patients with PHT died, but from causes unrelated to PHT.
Conclusion: Primary and secondary PHT are equally common in SLE patients. Secondary PHT is often multi-factorial, and Raynaud's phenomenon may be a marker for the severity of PHT in this group of patients.
Key Words: hypertension • pulmonary • Lupus erythematosus, systemic • Raynaud's phenomenon • Singapore
Lupus, Vol. 9, No. 5,
338-342 (2000)
DOI: 10.1191/096120300678828361
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Prabu, K. Patel, C.-S. Yee, P. Nightingale, R. D. Situnayake, D. R. Thickett, J. N. Townend, and C. Gordon
Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus
Rheumatology,
December 1, 2009;
48(12):
1506 - 1511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Quadrelli, C Alvarez, S. Arce, L Paz, J Sarano, E. Sobrino, and J Manni
Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies
Lupus,
October 1, 2009;
18(12):
1053 - 1060.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui
Interstitial lung disease guideline
Thorax,
September 1, 2008;
63(Suppl_5):
v1 - v58.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C P Denton, J E Pope, H-H Peter, A Gabrielli, A Boonstra, F H J van den Hoogen, G Riemekasten, S De Vita, A Morganti, M Dolberg, et al.
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
Ann Rheum Dis,
September 1, 2008;
67(9):
1222 - 1228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Swigris, A. Fischer, J. Gilles, R. T. Meehan, and K. K. Brown
Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Chest,
January 1, 2008;
133(1):
271 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kasparian, A. Floros, E. Gialafos, M. Kanakis, S. Tassiopoulos, N. Kafasi, and G. Vaiopoulos
Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus
Lupus,
July 1, 2007;
16(7):
505 - 508.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M.Y. Mok, P.L. Tsang, Y.M. Lam, Y. Lo, W.S. Wong, and C.S. Lau
Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
Lupus,
April 1, 2007;
16(4):
279 - 285.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C P Denton, M Humbert, L Rubin, and C M Black
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
Ann Rheum Dis,
October 1, 2006;
65(10):
1336 - 1340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Galie, A Manes, K V Farahani, F Pelino, M Palazzini, L Negro, S Romanazzi, and A Branzi
Pulmonary arterial hypertension associated to connective tissue diseases
Lupus,
September 1, 2005;
14(9):
713 - 717.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J.,
December 2, 2004;
25(24):
2243 - 2278.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S R Johnson, D D Gladman, M B Urowitz, D Ibanez, and J T Granton
Pulmonary hypertension in systemic lupus
Lupus,
July 1, 2004;
13(7):
506 - 509.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Mukerjee, D. St. George, C. Knight, J. Davar, A. U. Wells, R. M. Du Bois, C. M. Black, and J. G. Coghlan
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis
Rheumatology,
April 1, 2004;
43(4):
461 - 466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Molina, E Lucero, S Luluaga, V Bellomio, A Spindler, and A Berman
Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy
Lupus,
April 1, 2003;
12(4):
321 - 323.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M.M. Hoeper
Pulmonary hypertension in collagen vascular disease
Eur. Respir. J.,
March 1, 2002;
19(3):
571 - 576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
